Our research group is dedicated to the interdisciplinary frontier of biomedical engineering and nanomedicine, with a particular emphasis on developing targeted molecular probes and intelligent micro/nanomaterial platforms for the precise diagnosis and treatment of major diseases. The main research directions include:

• Targeted Nanotheranostic Platforms: Utilizing biomimetic strategies such as red blood cell and neuron membrane camouflage to develop disease-specific molecular probes, significantly enhancing the sensitivity and specificity of multimodal imaging techniques including photoacoustic, magnetic resonance, and fluorescence imaging.

• Stimuli-Responsive Composite Materials: Designing nanofibers, hydrogels, and core-shell composite structures with microenvironmental responsiveness (e.g., tumor or ischemic brain conditions) to enable controlled drug release and real-time therapeutic monitoring.

• Microneedle-Based Precision Drug Delivery: Developing intelligent microneedle systems integrating imaging and therapy for non-invasive, image-guided delivery in diseases such as glioma, brain trauma, and neurodegenerative disorders.

• Diagnosis and Therapy of Neurological Diseases: Investigating pathological mechanisms of brain injury, ischemia, and neuroinflammation, and constructing brain-targeted delivery systems capable of crossing the blood-brain barrier for precise lesion localization and intervention.

Our group emphasizes an integrated “material–imaging–therapy” approach, promoting innovation across molecular probe design, multimodal imaging, and intelligent therapeutic systems. We aim to achieve breakthroughs in early diagnosis, targeted therapy, and personalized medicine for cancer and neurological diseases, contributing to national health strategies and the development of advanced medical technologies.